Cover of Orphans and Incentives

Orphans and Incentives

Developing Technology to Address Emerging Infections

Workshop Report

; Editors: Polly F Harrison and Joshua Lederberg.

Washington (DC): National Academies Press (US); .
ISBN-10: 0-309-05941-0ISBN-13: 978-0-309-05941-1
Copyright © 1997, National Academy of Sciences.


This workshop of the Institute of Medicine's Forum on Emerging Infections set out to learn from experience what has been done and what is needed for the public and private sectors to collaborate effectively and productively for the health of the public. The emphasis was on cooperation in those product areas where returns from the market might be perceived as too small or too complicated by other factors to compete in industrial portfolios with other demands for investment. Quintessential examples of such products are vaccines, and in some instances therapies, for the diseases of children, for malaria, and for HIV/AIDS. Each of these offers lessons for attempts to deal systematically with emerging infectious diseases. While there are differences between the public health requirements of developing countries and industrialized countries, the growth of the middle class in the former and the vulnerability of the latter to diseases once thought to reside permanently “offshore” are doing much to narrow those differences.

The primary study case for the workshop was the Children's Vaccine Initiative (CVI), formally established in 1991 as the first comprehensive effort to yoke public- and private-sector scientific advances to a global public health priority through purposive intersectoral collaboration. The lessons learned from the CVI were integrated at the workshop with other experience from disease-focused efforts, notably malaria and HIV/AIDS. The purpose of this report was to integrate that learning and the tasks it suggests as points of reference for further action.

Support for this project was provided by Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases/NIH, Veterans Administration, Department of State, Food and Drug Administration, several private pharmaceutical companies, private foundations and associations.

The views presented are those of the Institute of Medicine Forum on Emerging Infections and are not necessarily those of the funding organizations.

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competencies and with regard for appropriate balance.

Copyright © 1997, National Academy of Sciences.
Bookshelf ID: NBK110019PMID: 23166966DOI: 10.17226/5948